anges.co.jpCrawled Oct 16, 2026
An overview of AnGes Inc.’s businesses, including pharmaceutical development, licensed products, and testing services (ACRL), as well as its research and development initiatives.
The page outlines development stages and progress for AnGes, Inc.’s HGF gene therapy product, NF-κB decoy oligonucleotide DNA, DNA vaccines, and other products.
Information for healthcare professionals, including product information and related materials from AnGes Inc.
The page describes AnGes, Inc.’s in-licensed products business, including Zokinvy’s use for progeria (HGPS/PDPL), its mechanism of action, and company initiatives.
AnGes Inc. announces its investor relations schedule. Dates are subject to change.
A list of IR news from AnGes Inc., including timely disclosures, financial results, and research and development updates.
The latest news from AnGes Inc., including IR news, announcements, and public relations blog posts.
AnGes Inc. offers mid-career and new graduate positions.
Profiles and biographies of AnGes Inc.’s directors and auditors, including the representative director and president.
The page covers AnGes Inc.’s corporate philosophy, mission, vision, company profile, leadership, and governance.
AnGes Inc.’s history, from its establishment in 1999 to the present.
AnGes Inc.’s company profile, including company information, offices, group companies, business model, and alliance partnerships.
The page describes AnGes Inc.’s ESG policies and activities related to the environment, society, and governance.
The page provides information to review before contacting AnGes Inc. and inquiry forms organized by purpose.
Contact AnGes Clinical Research Laboratory (ACRL), a laboratory testing facility for rare genetic diseases, with inquiries about its testing services.
The page provides an inquiry form for media representatives seeking interviews or materials. The company’s Corporate Communications and Investor Relations team will follow up.
AnGes, Inc. is a drug-discovery biotech venture researching and developing biopharmaceuticals and gene therapies.
Information on AnGes Inc.’s privacy policy and its approach to handling personal information.
Information on the disclaimer relating to AnGes Inc.’s investor relations information.
Information on the terms of use of the AnGes Inc. website, including intellectual property rights, disclaimers, and governing law.
Information on the social media guidelines for operating AnGes Inc.’s official social media accounts.
